GLG News by Adderall XR Prescribers (US)

The apparent connection of one event and another (in this case being conscientious and having a delayed onset of Alzheimer's) may not be what it seems.

Vanda Pharmaceuticals has filed an NDA for iloperidone, an atypical antipsychotic agent with mixed 5-HT2a and D2 receptor antagonism, for the treatment of schizophrenia. While the drug, standing alone against others in the ‘atypical’ class, might not stand out that much (in particular, its efficacy)...

Dov Pharmaceutical’s triple reuptake inhibitor (“TRI”; acts on serotonin, norepinephrine, dopamine) 21, 947 is still early in development with Phase I studies but potentially offers an antidepressant with unique features, in particular its side effect of weight loss. This may not seem like a major paradigm...

There is a clinical need for safer, well-tolerated hypnotic agents – that work. Actelion’s almorexant (an orexin antagonist) and Sanofi-Aventis’ eplivanserin, a 5HT2A receptor antagonist, are two of the lead sleep drugs that offer something new as compared to existing hypnotic agents [ie Ambien/Ambien...

Lilly is currently leader in Psychiatry with 4 active medications with great marketing for Psychiatry and Primary care physician. New compound that has a unique mechanism on Metabotropic Glutamate 2/3 Receptors, can work on Schizophrenia and other Psychiatric diagnosis. This is great opportunity...

As a physician and researcher, although not an expert in bariatrics, I find this untested and illogical procedure very frightening.  It has tremendous potential for harm and no logical reason why it should work.

Lily’s glutamate modulator LY2140023 is an investigational new drug with favorable Phase II results in a randomized, placebo-controlled trial for treating schizophrenia in a head-to-head comparison with olanzapine and placebo. Features of this drug which make it particularly appealing at this stage...

There is significant clinical need for effective, well-tolerated, low-risk hypnotic agents that can be used safely over the long term. On the surface, Actelion’s almorexant, a novel hypnotic agent acting as an orexin receptor antagonist, fits some of this profile and demonstrates statistical benefit...

The results of this study come as no surprise to those of us who  engage in Alzheimer's research and who actively evaluate and treat patients with Alzheimer's.  The real "surprise" is that there are so many patients with severe Alzheimer's who, unfortunately, have not already been placed...

Acetlion recently reported that Almorexant, a selective orexin receptor antagonist, dose-dependently increased total sleep time in primary insomniacs when compared to placebo.